Cafepharma Today

June 2 2025 - Gilead's CAR-T cell therapy shows promise in deadly brain cancer
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
Sanofi expands rare immunology portfolio with Blueprint buyout
Moderna's next-gen COVID shot gets FDA backing with some limitations
BioNTech flips its cancer bispecific to BMS for a big profit
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Mazor Robotics' Renaissance robot-assisted surgical system treats its 1st Parkinson's patient with a deep-brain stimulation implant
Mass Device
Wednesday, September 4, 2013 - 9:25am
tags:
Mazor Robotics, Renaissance robot-assisted surgical system, Parkinson's Disease, devices
AstraZeneca reverses $285 mln charge as cancer trial starts
Reuters
Wednesday, September 4, 2013 - 9:19am
tags:
AstraZeneca, olaparib, ovarian cancer
Rockwell Medical: Expecting Good Cruise II Data In September
Seeking Alpha
Wednesday, September 4, 2013 - 9:16am
tags:
Rockwell Medical, Calcitriol, generics, dialysis, SFP
Princeton Drug Royalties Spark Suit Over Tax Exemption
Bloomberg
Wednesday, September 4, 2013 - 9:14am
tags:
Princeton, drug royalties
Takeda Put Actos Sales Ahead of Consumer Safety, Lawyer Says
Bloomberg
Wednesday, September 4, 2013 - 9:05am
tags:
Takeda, Actos, bladder cancer, diabetes
AstraZeneca Reports Onglyza Data
Yahoo/Zacks
Wednesday, September 4, 2013 - 8:57am
tags:
Onglyza, AstraZeneca, diabetes
How Congress Encourages Shortages Of Cancer Drugs
Forbes
Tuesday, September 3, 2013 - 4:21pm
tags:
drug shortages
ArQule to cut liver cancer drug dose on safety concerns
Reuters
Tuesday, September 3, 2013 - 4:20pm
tags:
Arqule, liver cancer, tivantinib
Are Biotech M&A Premiums Already Built In? Valuations Do Matter
Seeking Alpha
Tuesday, September 3, 2013 - 4:19pm
tags:
biotech, M&A, ONYX Pharmaceuticals, Alexion, Biomarin, Incyte, Medivation, Pharmacyclics, Regeneron, Seattle Genetics
Safety Concerns May Prevent FDA Approval Of Ligand's Drug Aprela
Seeking Alpha
Tuesday, September 3, 2013 - 4:17pm
tags:
FDA, Ligand, Aprela, menopause, post-menopausal osteoporosis
Targeting An Untapped Female Sexual Dysfunction Drug Market
Seeking Alpha
Tuesday, September 3, 2013 - 11:23am
tags:
female sexual dysfunction, Osphena, Shionogi, flibanserin, Sprout Pharmaceuticals, bremelanotide, Palatin, Femprox, Apricus Biosciences
Coherus inks $246M Baxter deal to develop Enbrel biosimilar
Fierce Biotech
Tuesday, September 3, 2013 - 11:19am
tags:
Coherus Biosciences, Baxter International, Enbrel, biosimilars, Amgen
Philips, J&J land Defense Dept. contracts worth up to $73M
Mass Device
Tuesday, September 3, 2013 - 11:15am
tags:
devices, defense contracts, government contracts, Philips, JNJ
Chinese Police Say Glaxo Practices Come From Unit: Xinhua
Bloomberg
Tuesday, September 3, 2013 - 11:08am
tags:
China, GSK
Is 'No Worse Than Placebo' Good Enough For New Diabetes Drugs?
Forbes
Tuesday, September 3, 2013 - 11:07am
tags:
diabetes, saxagliptin, alogliptin, AstraZeneca, Bristol-Myers Squibb, Takeda
3 Great Reasons Why GlaxoSmithKline plc Is Set To Take Off
Motley Fool
Tuesday, September 3, 2013 - 11:06am
tags:
GSK, M&A, dividends
ImClone’s Waksal Back in Biotech With Plans for Spinouts
Bloomberg
Tuesday, September 3, 2013 - 10:45am
tags:
ImClone, Sam Waksal, biotech, Kadmon
Simultaneous Applications Submitted to EMA and FDA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder
Reuters
Tuesday, September 3, 2013 - 10:43am
tags:
EMA, FDA, siltuximab, multicentric Castleman disease
Esperion's drug lowers blood fat in mid-stage study
Reuters
Tuesday, September 3, 2013 - 10:40am
tags:
Esperion Therapeutics, ETC-1002
Amgen, Cytokinetics Report Mixed Results For Heart Failure Drug
TheStreet.com
Tuesday, September 3, 2013 - 10:39am
tags:
Amgen, Cytokinetics, heart failure, Omecamtiv Mecarbil

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.